This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
28 Sep 2011

Boehringer Ingelheim Receives EU Approval for Viramune Once-daily Formulation

Boehringer Ingelheim has received European approval for its once-daily Viramune tablets for HIV treatment.

German drug maker Boehringer Ingelheim has received EU approval for its Viramune (nevirapine) prolonged-release once-daily formulation, indicated for the treatment of HIV-1 infection.

 

The approval is based on results from clinical trials that confirmed the therapeutic benefits of nevirapine when administered in a once-daily formulation.

 

The VERxVE trial evaluated the antiviral efficacy and safety of once-daily nevirapine 400mg compared to twice-daily nevirapine 200mg. The TRANxITION trial examined the efficacy and safety of switching virologically suppressed patients from nevirapine immediate-release 200mg twice-daily to nevirapine prolonged-release 400mg once-daily.

 

Related News